Stock Track | Hims & Hers Health Soars 6.65% After Hours on Strong Q3 Results and Wegovy Partnership Talks-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

Stock Track | Hims & Hers Health Soars 6.65% After Hours on Strong Q3 Results and Wegovy Partnership Talks

Stock Track2025-11-04

Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.

The telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. Earnings per share came in at $0.06, while net income reached $16 million. The strong performance was driven by a 21% year-over-year increase in subscribers to 2.47 million and a 19% rise in monthly online revenue per average subscriber to $80.

Adding to investor optimism, Hims & Hers raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, up from previous estimates. The company also revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through the Hims & Hers platform. This potential partnership could significantly expand the company's offering in the booming weight loss market, though no definitive agreement has been reached yet.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1189614729?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189614729","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 6.65% After Hours on Strong Q3 Results and Wegovy Partnership Talks","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.</p>\n\n<p>The telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. Earnings per share came in at $0.06, while net income reached $16 million. The strong performance was driven by a 21% year-over-year increase in subscribers to 2.47 million and a 19% rise in monthly online revenue per average subscriber to $80.</p>\n\n<p>Adding to investor optimism, Hims & Hers raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, up from previous estimates. The company also revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through the Hims & Hers platform. This potential partnership could significantly expand the company's offering in the booming weight loss market, though no definitive agreement has been reached yet.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 6.65% After Hours on Strong Q3 Results and Wegovy Partnership Talks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 6.65% After Hours on Strong Q3 Results and Wegovy Partnership Talks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 05:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.</p>\n\n<p>The telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. Earnings per share came in at $0.06, while net income reached $16 million. The strong performance was driven by a 21% year-over-year increase in subscribers to 2.47 million and a 19% rise in monthly online revenue per average subscriber to $80.</p>\n\n<p>Adding to investor optimism, Hims & Hers raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, up from previous estimates. The company also revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through the Hims & Hers platform. This potential partnership could significantly expand the company's offering in the booming weight loss market, though no definitive agreement has been reached yet.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1189614729","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189614729","pubTimestamp":1762205660,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪|Hims&Hers Health盘后飙升6.65%，得益于强劲的第三季度业绩和Wegovy合作谈判","themeId":"6b43f5868e1a5ac8f736ff2144c2c120","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.\nThe telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. Earnings per share came in at $0.06, while net income reached $16 million. The strong performance was driven by a 21% year-over-year increase in subscribers to 2.47 million and a 19% rise in monthly online revenue per average subscriber to $80.\nAdding to investor optimism, Hims & Hers raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, up from previous estimates. The company also revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through the Hims & Hers platform. This potential partnership could significantly expand the company's offering in the booming weight loss market, though no definitive agreement has been reached yet.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}